# Prognosis in UC After First Biological

> **NCT05530122** · — · COMPLETED · sponsor: **Tampere University Hospital** · enrollment: 192 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **BIOLOGICAL:** infliximab, adalimumab, golimumab, vedolizumab, ustekinumab

## Key facts

- **NCT ID:** NCT05530122
- **Lead sponsor:** Tampere University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2020-01
- **Final completion:** 2022-08-26
- **Target enrollment:** 192 (ACTUAL)
- **Last updated:** 2022-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05530122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05530122, "Prognosis in UC After First Biological". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05530122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*